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Debate on human aging and lifespan
Mohammad A. Rafi1*, Abass Alavi2
1Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvanian, USA
2Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
In a paper entitled “Evidence for a limit to human lifespan” by Dong et al that was published in Nature Vol. 538 (October 13, 2016),1 the authors concluded 
that human lifespan is limited to 115 years and the 
probability of a lifetime exceeding 125 in any given year 
is less than 1 in 10 000. After about 8 months, the topic 
is now up for debate again. Five brief communications 
from different research groups have appeared in Nature 
Vol. 546 (June 29, 2017),2-6 all disagreeing with the paper’s 
conclusion that the human lifespan is limited to 115 
years. The critics have analyzed the paper from different 
viewpoints. The arguments focus primarily on different 
aspects of the statistical analysis, the limited availability 
of data, the splitting of the study period into two ranges 
(1968–1994 and 1995–2006), the failure to collect and 
verify the lifespan of extremely long-lived individuals, and 
the disregard for possible other trajectories. However, the 
authors of the paper have rejected all of these critics in 
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Article Info Summary
The issue of human lifespan has long been a matter of controversy among scientists. In spite of 
the recent claim by Dong et al that human lifespan is limited to 115 years, with the mounting 
improvements in biotechnology and scientific understanding of aging, we may be confident that 
aging will slow down over the course of the current century extending human longevity much 
longer than 115 years.
Authors' Biosketch 
Mohammad Rafi received his PhD in Animal Biology from the University of Montpellier, France, in 1970. He 
taught Cell and Molecular Biology for over 17 years at the School of Science, Tabriz University, Iran, where 
he also served as Chair of the Department of Animal Biology. He is currently a Professor of Neurology in 
the Department of Neurology with a joint appointment in the Department of Neurosciences at Thomas 
Jefferson University in Philadelphia, USA. Though he has worked on several lysosomal storage diseases, his 
main research interest is gene therapy of neurodegenerative disorders using animal models of globoid cell 
leukodystrophy (Krabbe disease). With successful AAVrh10-mediated treatment of murine and canine models, his research is 
moving towards the treatment trials of human patients.
Abass Alavi, MD is a distinguished professor in the Department of Radiology at the Hospital of the University 
of Pennsylvania (Philadelphia). Professor Alavi is known for his exceptional achievements in the field of 
PET as well as the structural imaging with MR and CT, including groundbreaking studies in cardiovascular 
diseases, neurologic disorders, and inflammation. He was awarded two honorary degrees from the European 
universities in 2016. Each was presented in the recognition of his great contributions to the molecular and 
structural imaging over the past 45 years. In May 2016, he received an honorary doctorate of medicine from 
the Medical University of Gdansk (Poland) at a ceremony hosted by the rector of the university, Dr. Janusz 
Morys (MD, Ph.D.) who highlighted Prof. Alavi’s excellent contributions to PET imaging that changed the 
direction of the diagnosis of diseases. In October 2016, Dr. Alavi was rewarded with an honorary doctor of medical sciences degree 
from the University of Southern Denmark (Odense) in a ceremony of the 50th anniversary of the university in the attendance of 
Queen Margrethe II of Denmark. In the celebration, Dr. Alavi’s outstanding contributions to the nuclear medicine and clinical 
molecular imaging were highly remarked. Professor Alavi has mentored and trained a large number of physicians and scientists 
in the United States, Europe, South America, and Asia. Dr. Alavi is a researcher of the highest international reputation - one of a 
kind in his class. With his unique background and education, he possesses the characteristics and qualities of a true polymath. 
He has been and remains to be the driving force behind the spread of knowledge about and the application of molecular imaging 
technology for the benefit of patients and society. Dr. Alavi was born in 1938 in Tabriz, a city in the Azerbaijani region of Iran. After 
becoming a physician, he moved to the United States in 1966 to advance his education in a science-based specialty. Together 
with chemists at Brookhaven National Laboratory (Upton, NY), Dr. Alavi, David Kuhl (MD) and Martin Reivich (MD) introduced 
18F-fluorodeoxyglucose (18F-FDG). Through this collaboration, in 1976, Dr. Alavi was the first to administer 18F-FDG to a human 
subject, producing tomographic images of the brain by means of a handmade Single-photon emission computed tomography 
(SPECT) device and planar whole-body images with a rectilinear scanner. His group pioneered the positron-emission tomography 
(PET) imaging of the normal brain and disorders (e.g., dementia, stroke, glioma, schizophrenia, and brain trauma). Professor Alavi 
has published over 1,000 articles in scholarly and high-impact journals. He is among the most cited physician/scientists in the 
United States, with current annual citations of 3,000 and citation indices of 50,000. Previously, Dr. Alavi has been recognized with 
honorary degrees from the University of Bologna (Italy), the University of the Sciences (Philadelphia, PA), and the Universities of 
Shiraz and Tabriz (Iran). He is a past recipient of the De Hevesy and Cassen awards from the Society of Nuclear Medicine and 
Molecular Imaging (SNMMI). He plays a central role in the establishment of the Aging Research Institute at Tabriz University of 
Medical Sciences in Iran. Prof. Alavi serves on the editorial board of several international journals, including Bioimpacts. 
Rafi and Alavi
BioImpacts, 2017, 7(3), 135-137136
different rebuttal letters (Nature Vol. 546) and defended 
their conclusion of a human lifespan limited to 115 years. 
The issue of human lifespan has long been a matter of 
controversy among scientists. According to Olshansky and 
Carnes,7 there are three opposing viewpoints on human 
longevity, those of “Futurists,” “Optimists,” and “Realists.” 
Futurists believe in the continuous extension of 
human life with no limitation. They rely on forthcoming 
improvements in different biotechnological domains that 
will dramatically transform the landscape of human aging 
and longevity toward a physical immortality and eternal 
youth. 
Optimists believe that the existing increase in life 
expectancy, which began during the last century, will 
continue its linear increase at about 2.5 years per decade. 
Optimists, too, rely on biomedical technologies not 
currently available and do not foresee any limit to a 
continuous increase in life expectancy. 
Realists, however, argue that human lifespan is 
biologically determined and that continuous increase in 
life expectancy is, practically, implausible. They believe 
that there are many factors interfering with the duration of 
human life, as well as with the lifespans of other organisms. 
Aging, itself, is a fact that, according to existing scientific 
knowledge, cannot be stopped or reversed. It may be 
slowed down, but it is unlikely to have a perceptible 
impact on life expectancy. Therefore, Realists believe in 
the existence of a life boundary that is like a warranty 
period or expiration date, limiting lifespan and, hence, 
longevity.7
There is no doubt that, due to scientific advances in 
biotechnology and medicine, human life expectancy 
has increased during the last century. According to 
the National Institute on Aging, while the average life 
expectancy for babies born in 1900 was only 47 years, it rose 
to 79 years in 1998. Meanwhile, the title for the longest life 
recorded in human history belongs to the French woman 
Jeanne Calment, who lived 122 years (1875-1997).8 It is 
also notable that the upward course in life expectancy 
has slowed down during the current century. While the 
precise limit to human longevity is arguable, based on the 
current state of our medical and biomedical knowledge, 
some limit or range of limit is necessary. Therefore, human 
immortality and eternal life, as supported by Futurists, 
appears to be out of the question. Clearly, the study done 
by Dong et al.1 suffers from restricted sample availability. 
A more realistic evaluation of human longevity requires 
not only a longer study duration, which would, in turn, 
provide an increased sample size but also a carefully 
designed study plan and data analyzing strategy. 
The increase in life expectancy during the last century 
was mostly due to improvements in public health and 
achievements in declining early age mortalities. In the 
future, the escalation in human lifespan will depend 
on healthier lifestyles and the availability of improved 
biomedical advances and biotechnologies. With scientific 
interventions and environmental improvements, we may 
be confident that aging will slow down over the course of 
the current century. 
Aging may be inevitable, but the rate of aging may not 
be so if we recognize the causes of aging. What appears 
to play a more influential role in limiting lifespan is the 
progressive accumulation of molecular damage inside the 
cells. While any kind of structural and molecular damage 
may profoundly affect cell function and accelerate the 
aging process, damage to DNA structure, because of 
its vital role in life, has been a focal point, giving rise to 
the “DNA damage theory of aging.” Both mitochondrial 
and nuclear DNA damage lead to the development 
of pathological conditions that accelerate aging and 
senescence. Fortunately, our cells are equipped with 
mechanisms that can efficiently repair these damages. 
However, over time, some of these repair mechanisms may 
fail or their function may be blocked by other molecules. 
Therefore, damaged DNA will remain unrepaired and, as 
time goes on, accumulate, disturbing cell function and 
affecting lifespan. 
One of the DNA repair pathways relies on the 
restoration activity of “poly-adenosine diphosphate–
ribose-polymerase 1” (PARP1). The repair function of 
this enzyme can be inhibited by another protein called 
“deleted in breast cancer 1” (DBC1). The DBC1 gene was 
originally found to be deleted in some breast cancer cells.9 
This protein seems to be involved in the regulation of 
cancer cell energy metabolism.10 A recent study by Li et 
al11 has revealed that both PARP1 and the oxidized form 
of “nicotinamide adenine dinucleotide” (NAD+) compete 
with each other in binding to the DBC1 protein, therefore, 
keeping PARP1 unblocked and capable of DNA repair. 
Experiments conducted in old mice,11 have shown 
that age-related DNA damage diminishes when the 
cellular level of NAD+ is increased. The outcome of 
these experiments suggests that as NAD+ levels decline 
with age, fewer NAD+ molecules are available to prevent 
DBC1 binding PARP1. Therefore, unblocked DBC1 will 
bind PARP1 and damaged DNA will remain unrepaired. 
The accumulation of the unrepaired DNA, over time, 
will gradually paralyze cell function. In an increased 
abundance of NAD+, the harmful action of DBC1 will 
be stopped and DNA repair with PARP1 will continue 
slowing down the aging process. 
Another study just published in Nature (July 26, 2017)12 
demonstrates the role of renewed neuro-stem cells 
(NSCs) in the hypothalamic region of the mouse brain. 
While the pivotal role of the hypothalamus in whole body 
aging was shown previously,13 in this study the authors 
demonstrated that besides the known neurogenesis role of 
the hypothalamic NSCs, these cells contribute greatly in 
the production of exosomal microRNAs (miRNAs) in the 
cerebrospinal fluid. These exosomes, which are linked to 
the neuro-stem cell function, and therefore, to whole body 
aging, can be produced from the cultured hypothalamic 
NSCs and delivered to the brain hypothalamic area. While 
the exosomal miRNAs production declines during aging, 
their increased level in the treated mice leads to slow down 
the aging process.12
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Given the crucial biological differences between mice 
and humans, the applicability of these treatments in 
humans and their positive results remain to be seen. In the 
best case of scenario, expecting an increase in average life 
expectancy for young generations of about 100 years and 
longevity over 125 years appears to be reasonable. 
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